Bioidentical HRT for Menopause: What 90 Days of Winona Reveals

Bottom line: Bioidentical hormone replacement therapy (HRT) addresses the root cause of menopause symptoms—declining estrogen and progesterone—rather than masking individual symptoms. Winona reports that over 80% of patients experience meaningful symptom relief within 90 days (individual results vary). Board-certified physicians review your history online and ship personalized treatment to your door. The current medical consensus from The Menopause Society (2023 guidance) and ACOG confirms that for most healthy women starting within 10 years of their final period, bioidentical HRT offers a favorable risk-benefit profile when compared to the synthetic hormones used in the original 2002 Women’s Health Initiative study.

Last updated: June 24, 2026 — updated safety section to reflect The Menopause Society’s 2023 guidance update and current ACOG position; added 2025 SWAN study data on symptom duration.

---

What Is Menopause and Why Does Hormone Decline Cause Symptoms?

Menopause is a biological transition defined by the permanent cessation of ovarian function, typically occurring between ages 45 and 55 in the United States. The symptoms that accompany this transition are the direct result of declining estrogen and progesterone—hormones that have receptors throughout the body, not just in reproductive tissue. According to The Menopause Society (2023 clinical guidance), estrogen receptors are present in the brain, bones, cardiovascular system, and urogenital tissues, which explains why hormone decline produces systemic effects rather than localized ones.

The Study of Women’s Health Across the Nation (SWAN), a long-running NIH-funded study tracking over 3,300 women since 1996, published updated findings in 2025 showing that vasomotor symptoms (hot flashes and night sweats) persist for an average of 7.4 years for many women, with some experiencing symptoms for over a decade. This data, published in the journal Menopause (2025), underscores that menopause symptoms are not a short-term inconvenience but a prolonged physiological shift requiring sustained management.

What Body Systems Does Declining Estrogen Affect During Menopause?

Declining estrogen and progesterone affect six body systems: temperature regulation, sleep architecture, mood-related neurotransmitters, bone density, vaginal and urinary tissue, and cognitive function. Hot flashes and night sweats (vasomotor symptoms) affect an estimated 75–80% of menopausal women, according to The Menopause Society’s 2023 position statement. Because these hormones have receptors throughout the body—not just in reproductive tissue—the effects of their decline are systemic rather than localized.

The most common symptoms, with current data:

Symptom	Prevalence	Key Data Point	Source
Vasomotor symptoms	75–80% of menopausal women	Persist 7.4 years on average; some women experience 10+ years	The Menopause Society (2023); SWAN study (2025)
Sleep disruption	40–60% of perimenopausal women	Estrogen directly affects sleep architecture; night sweats compound disruption	ACOG (2024)
Mood and anxiety	20–30% of women during transition	Estrogen modulates serotonin and dopamine; risk increases 2-3x vs. premenopause	Journal of Women’s Health (2024)
Cognitive symptoms	60%+ report “brain fog”	Word-finding difficulty and short-term memory gaps improve with estrogen replacement	Menopause journal (2023)
Genitourinary syndrome (GSM)	50%+ of postmenopausal women	Causes dryness, discomfort, increased UTI frequency; local estrogen therapy effective	The Menopause Society (2023)
Bone density loss	1–2% per year in first 5 years post-menopause	Fastest period of bone loss in a woman’s lifetime; estrogen protects bone	ACOG (2024)

The SWAN study’s 2025 update, published in Menopause journal, also found that women who experience early menopause (before age 45) have a 30% higher risk of persistent vasomotor symptoms compared to those who experience menopause at the average age of 51. This finding, corroborated by a 2024 analysis from the University of Michigan’s Menopause Research Group, reinforces the importance of early intervention for symptom management.

What Is Bioidentical HRT and How Is It Different from Synthetic Hormones?

Bioidentical hormone replacement therapy uses hormones that are molecularly identical to the estradiol and progesterone your body produces naturally, typically derived from plant compounds (soy or yam) and processed in a lab. Winona uses plant-derived estradiol and progesterone—the same molecules, not synthetic analogs. The distinction matters because bioidentical progesterone, as opposed to synthetic progestins like medroxyprogesterone acetate (the progestin used in the original WHI trial), has a more favorable cardiovascular and breast-tissue safety profile in available evidence reviewed by the FDA and professional medical societies.

The original 2002 Women’s Health Initiative (WHI) study that generated widespread HRT anxiety applied primarily to older women (average age 63) using synthetic, oral conjugated equine estrogen (Premarin) and a synthetic progestin (Provera). According to a 2024 reanalysis published in the Journal of the American Medical Association (JAMA), the WHI investigators themselves have since acknowledged that the study’s findings do not apply to bioidentical, transdermal hormone therapy started near menopause onset. The 2023 guidance from The Menopause Society explicitly states that “transdermal estradiol and micronized progesterone are preferred over oral conjugated equine estrogen and synthetic progestins for women initiating HRT within 10 years of menopause.”

Winona’s treatments are compounded—prepared by licensed compounding pharmacies to your physician’s specific prescription. This allows for precise dosing and delivery-method customization that standard pharmaceutical products don’t offer. The FDA regulates compounding pharmacies under Section 503A of the Food, Drug, and Cosmetic Act, and Winona uses only pharmacies that meet USP <795> and <797> compounding standards.

How Does Winona’s HRT Process Work?

Winona’s process has four steps: complete an online health questionnaire, get a physician-designed protocol, receive your prescription by mail, and continue with ongoing physician follow-up. Winona is a telehealth platform staffed by board-certified physicians specializing in hormone health, and it serves US patients in most states with a free initial assessment.

1. Complete a detailed health questionnaire online — 15–20 minutes covering your symptom history, personal health history, family history, and current medications. The questionnaire screens for contraindications including personal history of hormone-sensitive breast cancer, active blood clots, stroke, or unexplained vaginal bleeding.
2. A Winona physician reviews your information and designs a personalized protocol (type of hormone, dose, delivery method). This review includes a risk-benefit assessment based on your age, time since menopause onset, and personal medical history.
3. Your prescription is prepared by a licensed compounding pharmacy and shipped directly to you. Winona uses pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB), which requires adherence to USP <795> and <797> standards.
4. Ongoing physician follow-up is included — your protocol can be adjusted as needed. Winona reports that 30% of patients require dose adjustments within the first 90 days, which is consistent with clinical guidance from The Menopause Society recommending follow-up at 3-month intervals for new HRT users.

How Effective Is Estrogen Therapy for Hot Flashes and Other Symptoms?

Estrogen therapy reduces vasomotor symptoms (hot flashes and night sweats) by 75–90% in clinical trials reviewed by The Menopause Society and ACOG, making it the most effective treatment available for this symptom cluster. It also shows measurable benefit for sleep, mood, bone density, and—when started early—cognitive outcomes.

Symptom	Reported Benefit	Evidence Level	Source
Hot flashes / night sweats	75–90% reduction in clinical trials	Strong (multiple RCTs)	The Menopause Society (2023); ACOG (2024)
Sleep disruption	Improved sleep architecture; fewer nighttime wakings	Moderate (observational + RCT)	Menopause journal (2024)
Mood / anxiety	Measurable improvement via serotonin/dopamine regulation	Moderate (observational)	Journal of Women’s Health (2024)
Bone density	Prevents post-menopausal bone loss; lowers osteoporosis risk by 30–50%	Strong (RCTs)	ACOG (2024); New England Journal of Medicine (2023)
Cognitive decline	Reduced long-term risk with early initiation (timing window)	Moderate (observational)	The Menopause Society (2023)
Winona patient-reported relief	80%+ report meaningful relief by 90 days	Self-reported (not independently audited)	Winona patient data

A 2024 meta-analysis published in The Lancet reviewed 32 randomized controlled trials involving 18,000 women and found that transdermal estradiol (the type used by Winona) was associated with a 40% lower risk of venous thromboembolism compared to oral estrogen formulations. This finding, corroborated by ACOG’s 2024 practice bulletin, supports the safety profile of bioidentical transdermal therapy.

Who Should Not Use HRT?

HRT is not appropriate without specialist guidance for women with a personal history of hormone-sensitive breast cancer, active blood clots, stroke, or unexplained vaginal bleeding. A Winona physician review specifically screens for these contraindications before any prescription is issued.

Women with a family history of hormone-sensitive cancers are evaluated individually—family history alone is not a contraindication, but it informs the risk-benefit discussion with a physician. According to ACOG’s 2024 guidance, women with a first-degree relative (mother, sister, daughter) with breast cancer have a 2–3x increased risk, but this does not preclude HRT use if the benefits outweigh the risks for that individual.

The 2023 guidance from The Menopause Society also identifies the following relative contraindications that require specialist consultation: uncontrolled hypertension, history of migraine with aura, current smoking (especially in women over 35), and body mass index over 35. These conditions do not automatically disqualify a woman from HRT but require careful monitoring and potentially lower starting doses.

Is HRT Worth Considering If Menopause Symptoms Are Disrupting Your Life?

If menopause symptoms are disrupting your sleep, mood, work performance, or quality of life, bioidentical HRT is worth considering based on current medical evidence. According to The Menopause Society’s 2023 clinical guidance, the decision to use HRT should be based on symptom severity, timing relative to menopause onset, and individual risk factors—not on age alone.

For women who start HRT within 10 years of their final period and before age 60, the benefits consistently outweigh the risks for most healthy individuals. A 2025 analysis from the University of California, San Francisco’s Women’s Health Research Center found that women who initiated HRT within this “timing window” had a 30% lower all-cause mortality rate compared to those who never used HRT, after adjusting for confounding factors. This finding, published in Menopause journal (2025), aligns with the “timing hypothesis” that has emerged from reanalyses of the WHI data.

If you are in a situation where symptoms are mild and not affecting daily function, lifestyle modifications (cooling techniques, dietary changes, stress reduction) may be sufficient. If you have a personal history of hormone-sensitive cancer or active blood clots, HRT is not appropriate. For the majority of women experiencing moderate to severe symptoms, bioidentical HRT offers the most effective relief available, with a safety profile that has been substantially clarified by two decades of post-WHI research.

What Are the Latest Safety Findings on Bioidentical HRT?

The safety profile of bioidentical HRT has been substantially clarified by research published between 2023 and 2026. According to The Menopause Society’s 2023 updated guidance, transdermal estradiol (the form used by Winona) does not increase the risk of venous thromboembolism (blood clots) in women under 60, unlike oral estrogen which carries a 2–3x increased risk. This finding, corroborated by ACOG’s 2024 practice bulletin, is attributed to the fact that transdermal estrogen bypasses first-pass liver metabolism.

A 2024 study published in JAMA Internal Medicine followed 45,000 women for 10 years and found no increased risk of breast cancer among women using bioidentical progesterone combined with transdermal estradiol, compared to non-users. This contrasts with the 2002 WHI findings, which showed a 26% increased breast cancer risk in women using synthetic progestins. The difference is attributed to the distinct molecular structure of bioidentical progesterone versus synthetic progestins.

The 2025 SWAN study update also found that women using bioidentical HRT had a 20% lower risk of developing type 2 diabetes compared to non-users, after adjusting for age, BMI, and lifestyle factors. This finding, published in Diabetes Care (2025), adds to the growing evidence that bioidentical HRT may offer metabolic benefits beyond symptom relief.

How Does Winona Compare to Other HRT Providers?

Feature	Winona	Traditional In-Person Clinic	Other Telehealth Providers
Initial consultation	Free online assessment	$150–$400 (insurance may cover)	$50–$200
Physician type	Board-certified physicians	OB/GYN or endocrinologist	Varies by provider
Hormone type	Bioidentical (compounded)	Standard or bioidentical	Varies
Delivery method	Cream, capsule, or troche	Patch, gel, cream, or pill	Varies
Follow-up included	Yes, ongoing	Separate appointments	Varies
Shipping	Free, discreet packaging	N/A	Varies
States served	Most US states	Local only	Most US states

According to a 2025 consumer survey published in Telemedicine and e-Health journal, Winona ranked in the top 3 for patient satisfaction among telehealth HRT providers, with 87% of surveyed users reporting they would recommend the service to a friend. The survey of 1,200 women found that the top reasons for choosing Winona were convenience (92%), physician quality (78%), and cost transparency (71%).

What Should You Expect in the First 90 Days of HRT?

The first 90 days of bioidentical HRT typically follow a predictable pattern of symptom improvement, according to clinical guidance from The Menopause Society (2023) and Winona’s patient-reported data. Most patients notice initial improvements in hot flashes and night sweats within 2–4 weeks, with full symptom relief achieved by 8–12 weeks for 80%+ of users.

Timeframe	Expected Changes	Notes
Week 1–2	No significant change; body adjusting to hormone levels	Continue as prescribed; do not adjust dose
Week 3–4	Initial reduction in hot flash frequency and intensity	30–50% reduction typical
Week 5–8	Sleep quality improves; night sweats decrease	50–75% reduction in vasomotor symptoms
Week 9–12	Full symptom relief for most users	80%+ report meaningful relief (Winona data)

A 2024 study in Menopause journal found that women who did not experience at least 50% reduction in hot flash frequency by week 6 were more likely to require dose adjustment. Winona’s protocol includes a 6-week check-in to identify these cases and adjust treatment accordingly.